CRA leading the way in analytics
In recent years, the adoption of advanced treatments in inflammatory bowel disease has evolved. Oral products have captured a significant share in ulcerative...
With new technologies driving step changes in biopharma, we can help you predict and plan for the next round of disruptive changes.
Engagements
- 01Estimating economic damages relating to type 2 diabetes drugA pharmaceutical company brought on a CRA consultant to estimate economic damages arising from alleged infringement and at-risk launch of a patented oral...View engagement